4-HO-EPT (4-hydroxy-N-ethyl-N-propyltryptamine) is a synthetic psychedelic tryptamine belonging to the 4-hydroxy tryptamine family — the same structural class as psilocin (4-HO-DMT). Unlike the 4-AcO compounds, which are prodrugs requiring metabolic activation, 4-HO-EPT is already in the active hydroxylated form and does not require conversion prior to receptor interaction. The compound features an ethyl and a propyl group on the terminal nitrogen, distinguishing it from the simpler symmetric analogs of psilocin.
4-HO-EPT is among the less-documented members of the 4-HO tryptamine series. Community reports suggest a psychedelic experience that shares the characteristic visual and cognitive alterations of the 4-hydroxy tryptamine family, with some users describing the experience as visually rich with a particular warmth and openness at moderate doses. The ethyl-propyl substitution pattern places it between the lighter MET/MPT analogs and the heavier DiPT analogs in terms of steric bulk, and the asymmetric alkyl substitution may contribute to a distinctive subjective character.
As with most novel psychedelic tryptamines, human pharmacological data is extremely limited, and the compound's safety and effect profile is primarily characterized through community experience reports and extrapolation from better-studied analogs. Active doses are typically in the 10–30 mg range, with duration of approximately 4–6 hours.
Safety at a Glance
High Risk- Threshold: 5–10 mg | Common: 15–25 mg | Strong: 25–40 mg
- Begin conservatively (10–15 mg) given limited documentation. Individual sensitivity varies.
- Toxicity: Acute Toxicity No formal toxicological data in humans. Safety profile is inferred from class membership (4-hydroxy tr...
- Overdose risk: Fatal overdose from 4-HO-EPT alone, at doses within the typical recreational range, is extremely ...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 3 hrs – 7 hrsHow It Feels
The onset of 4-HO-EPT is gentle and unassuming. Thirty to forty-five minutes after ingestion, a soft warmth begins to build in the body, accompanied by a mild tingling in the scalp and fingertips. There is little to no nausea, and the transition from baseline feels more like a gradual turning of a dial than a threshold crossing. Colors become slightly more vivid, edges soften almost imperceptibly, and there is a quiet sense of heightened presence — the world does not look radically different, but it seems somehow more worthy of attention.
Over the next hour, the visual effects develop to a gentle plateau. Surfaces may show a subtle breathing quality — slow, rhythmic expansions and contractions that are easy to miss unless one is looking for them. Textures become more interesting: the grain of wood, the weave of fabric, the patterns in clouds all seem to reveal detail that was previously overlooked. Colors warm slightly, taking on a soft, golden quality. Closed-eye visuals are modest but pleasant: slow-moving fields of pastel color, simple geometric forms that drift and rotate lazily, and occasional fleeting imagery that dissolves before it fully resolves.
The peak, arriving around ninety minutes and lasting one to two hours, is characterized by its mildness and accessibility. The headspace is light and clear — thoughts flow easily, conversation is natural, and there is no sense of cognitive impairment or disorientation. A gentle mood lift pervades the experience, a quiet contentment that makes simple activities feel rewarding. Music is subtly enhanced, with slightly increased emotional resonance and spatial depth. The body feels comfortable and relaxed, pleasantly heavy without being sedated. This is not a substance that overwhelms or challenges; it is more akin to a gentle widening of the aperture of perception.
The comedown is smooth and almost imperceptible, the mild enhancement gradually fading over one to two hours until baseline is reached. The total duration is typically three to five hours. There is a brief, subtle afterglow of quiet wellbeing, and sleep comes easily afterward. The overall experience of 4-HO-EPT is that of a psychedelic whisper — faint, gentle, and easily overlooked, but carrying a genuine softness that can be appreciated for its own understated character.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(7)
- Body load— A diffuse, heavy physical discomfort involving tension, pressure, and malaise in the torso and limbs...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Temperature regulation disruption— Impaired thermoregulation causing unpredictable fluctuations between feeling hot and cold, with risk...
Cognitive & Perceptual Effects
Visual(17)
- After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
- Brightness alteration— Perceived increase or decrease in environmental brightness beyond actual illumination levels, common...
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
- Depth perception distortions— Alterations in how the distance of objects within the visual field is perceived, causing layers of s...
- Diffraction— The experience of seeing rainbow-like spectrums of color and prismatic halos embedded within bright ...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
- Perspective distortions— Distortion of perceived depth, distance, and size of real objects, making things appear closer, furt...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Symmetrical texture repetition— Textures appear to mirror and tessellate across surfaces in intricate, self-similar symmetrical patt...
- Tracers— Moving objects leave visible trails of varying length and opacity behind them, similar to long-expos...
- Transformations— Objects and scenery undergo perceived visual metamorphosis, smoothly shapeshifting into other recogn...
- Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
Cognitive(12)
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Anxiety suppression— A partial to complete suppression of anxiety and general unease, producing a calm, relaxed mental st...
- Cognitive euphoria— A cognitive and emotional state of intense well-being, elation, happiness, and joy that manifests as...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
- Personal bias suppression— A decrease in the personal, cultural, and cognitive biases through which one normally filters their ...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Thought loops— Becoming trapped in a repeating cycle of thoughts, actions, and emotions that loops every few second...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
Multi-sensory(1)
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
Transpersonal(2)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
- Unity and interconnectedness— A profound sense that identity extends beyond the self to encompass other people, nature, or all of ...
Pharmacology
5-HT2A Partial Agonism
4-HO-EPT, as a free phenol 4-hydroxy tryptamine, directly acts as a partial agonist at serotonin 5-HT2A receptors without requiring metabolic activation. This is the primary mechanism underlying psychedelic tryptamine effects — 5-HT2A activation in the prefrontal cortex leads to increased glutamatergic signaling and the characteristic disruption of sensory hierarchical processing.
The asymmetric N-ethyl-N-propyl substitution pattern of 4-HO-EPT creates a molecule of intermediate steric bulk relative to the symmetric dialkyl analogs (MET = methyl-ethyl, EPT = ethyl-propyl, DiPT = diisopropyl). The receptor binding affinity and intrinsic efficacy of 4-HO-EPT at 5-HT2A have not been formally characterized in published binding studies.
Additional Receptor Interactions
Like other 4-hydroxy tryptamines, 4-HO-EPT likely interacts with multiple serotonin receptor subtypes. 5-HT1A partial agonism would contribute anxiolytic and body load components; 5-HT2C activity would affect mood regulation. The full receptor binding profile has not been published.
Pharmacokinetics
4-HO-EPT does not require prodrug activation. Onset after oral administration: approximately 30–60 minutes. Peak: 1.5–3 hours. Duration: 4–6 hours. The ethyl-propyl substitution is expected to slow metabolic N-dealkylation slightly compared to simpler analogs. No formal pharmacokinetic data available.
Tolerance
Rapid functional tolerance within 24–48 hours; complete cross-tolerance with other 5-HT2A agonist psychedelics. Recovery over approximately 5–7 days.
Detection Methods
Urine Detection
4-HO-EPT is not targeted by standard immunoassay-based urine drug screens. Specialized LC-MS/MS methods can detect 4-substituted tryptamine metabolites in urine for approximately 24 to 48 hours after ingestion. The detection window is relatively short compared to many other drug classes due to the rapid hepatic metabolism and renal clearance of tryptamine compounds. Psilocin (4-HO-DMT) is the most commonly targeted analyte in specialized tryptamine panels, and structural analogs may or may not be captured depending on the specific method.
Blood and Serum Detection
Blood detection windows for 4-HO-EPT are short, typically 4 to 12 hours after oral ingestion. Peak plasma concentrations of the active metabolite occur within 1 to 2 hours. The rapid first-pass metabolism means that parent compound concentrations in blood are often negligible for 4-AcO prodrugs, while 4-HO compounds themselves are measured directly. LC-MS/MS is required for reliable serum detection at the low concentrations involved.
Standard Drug Panel Inclusion
4-HO-EPT is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. Tryptamines do not cross-react with immunoassay targets for any of the standard panel analytes (amphetamines, cannabinoids, cocaine metabolites, opiates, PCP, benzodiazepines, or barbiturates). Detection requires a specific request for tryptamine or novel psychoactive substance testing at a reference laboratory. Some extended forensic panels include psilocin, which may capture certain 4-substituted tryptamines, but this coverage is not guaranteed for all structural variants.
Confirmatory Methods
Confirmatory identification of 4-HO-EPT relies on LC-MS/MS with reference standards specific to the compound or its expected metabolites. GC-MS can also be used following appropriate derivatization. Immunoassay-based methods for psilocybin and psilocin exist but show variable cross-reactivity with structural analogs and are not considered reliable for novel 4-substituted tryptamines. Reference laboratories specializing in novel psychoactive substances offer the most comprehensive detection capabilities.
Reagent Testing (Harm Reduction)
The Ehrlich reagent is the primary harm reduction tool for 4-HO-EPT. A sample placed on the reagent should produce a purple to violet color change, confirming the presence of an indole ring system characteristic of tryptamines. This reaction is shared with LSD, psilocybin, DMT, and all indole-containing compounds, so it confirms the general class but not the specific identity. The Hofmann reagent provides a confirmatory blue to violet reaction for tryptamines. The Marquis reagent typically shows no reaction or a dark brown discoloration with 4-substituted tryptamines. A positive Ehrlich result significantly reduces the probability that the substance is a dangerous substitute such as an NBOMe compound.
Interactions
| Substance | Status | Note |
|---|---|---|
| 3-FMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 4-MMC | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 8-Chlorotheophylline | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Adrafinil | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Anandamide | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| Cannabis | Uncertain | — |
| 1,3-Butanediol | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 25E-NBOH | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T-2 | Low Risk & Synergy | Cross-tolerance exists; effects compound |
History
Origins
4-HO-EPT belongs to the family of 4-substituted tryptamines that were systematically mapped out through the work of Albert Hofmann, Franz Troxler, and later Alexander Shulgin. The compound is the direct hydroxylated analog of EPT (N-ethyl-N-propyltryptamine) and shares structural kinship with iprocin (4-HO-DiPT) and psilocin (4-HO-DMT).
Research Chemical Context
4-HO-EPT entered the research chemical landscape considerably later and with less fanfare than the 4-HO-DMT and 4-HO-MiPT analogs. It represents one of the less commonly encountered members of the 4-HO tryptamine class, available sporadically through research chemical vendors and documented primarily through community experience reports. No formal pharmacological or clinical research has specifically examined this compound.
Harm Reduction
Verification
Test with Ehrlich reagent (purple/violet for indole tryptamines) before use. Given the limited availability and documentation of 4-HO-EPT, verifying that the substance obtained is what it claims to be is particularly important.
Dosing
- Threshold: 5–10 mg |Common: 15–25 mg |Strong: 25–40 mg
- Begin conservatively (10–15 mg) given limited documentation. Individual sensitivity varies.
- Use a milligram-accurate scale.
Prepare Thoughtfully
Given the limited community documentation, approach 4-HO-EPT with particular caution and preparation. Research available experience reports. Ensure a comfortable, known environment and a sober companion for first experiences.
Avoid Dangerous Combinations
Absolute contraindications: lithium, MAOIs, tramadol. Significant risk: dissociatives, cannabis, stimulants.
Toxicity & Safety
Acute Toxicity
No formal toxicological data in humans. Safety profile is inferred from class membership (4-hydroxy tryptamines, which include the extensively studied psilocin) and community-accumulated experience. The class as a whole demonstrates very low acute physiological toxicity.
Physiological Effects
Mild to moderate sympathomimetic effects characteristic of the tryptamine class: pupil dilation, moderate tachycardia, possible nausea during onset. The longer alkyl chains may increase the likelihood of a physical "body load" — somatic heaviness, tension, or temperature dysregulation — relative to simpler analogs such as 4-HO-DMT or 4-HO-MET.
Psychological Risks
- Anxiety and panic — Risk increases with dose, unfamiliar settings, and psychological unpreparedness.
- Psychosis induction — Contraindicated for those with personal or family history of schizophrenia or psychotic disorders.
- HPPD — Rare but possible, as with all 5-HT2A agonist psychedelics.
Drug Interactions
- MAOIs — Potentiation; serotonin syndrome risk; avoid.
- Lithium — Seizure risk; absolute contraindication.
- Cannabis — Significant unpredictable amplification.
- SSRIs/SNRIs — May reduce effects; abrupt discontinuation of antidepressants for this purpose carries serious risks.
Addiction Potential
not habit-forming
Overdose Information
Fatal overdose from 4-HO-EPT alone, at doses within the typical recreational range, is extremely unlikely based on the available evidence for classical psychedelics. The therapeutic index for most psychedelics is very wide.
However, psychological emergencies can occur and require appropriate response:
- Severe anxiety, panic, or psychotic episodes
- Dangerous behavior due to impaired reality testing
- Self-harm in the context of a distressing experience
Emergency management: If someone is experiencing a severe adverse reaction, move them to a calm, quiet environment. Speak reassuringly. Do not restrain unless there is immediate danger. Benzodiazepines (if available and the person is conscious and able to swallow) can reduce acute anxiety. If psychotic symptoms, self-harm risk, or medical distress is present, seek emergency medical attention.
Medical attention: Seek help immediately for seizures, extremely elevated body temperature, signs of serotonin syndrome (agitation, tremor, diarrhea, rapid heart rate), or if the substance consumed is uncertain.
Tolerance
| Full | almost immediately after ingestion |
| Half | 3 days |
| Zero | 7 days |
Cross-tolerances
Legal Status
Due to its relative obscurity, the possession and sale of 4-HO-EPT is unscheduled in most countries.
Germany: 4-HO-EPT is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person, placing it on the market and trading is punishable. Possession is illegal but not punishable. The legislator considers it possible that orders of 4-HO-EPT are punishable as an incitement to place it on the market.
Switzerland: 4-HO-EPT is not controlled under Buchstabe A, B, C and D. It could be considered legal.
United Kingdom: 4-HO-EPT is a Class A drug in the United Kingdom as a result of the tryptamine catch-all clause.
United States: 4-HO-EPT is unscheduled in the United States. It may be considered an analogue of psilocin (which is a Schedule I drug under the Controlled Substances Act). As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.
Responsible use
Research chemical
EPT
Tryptamine
4-HO-EPT (Wikipedia)
4-HO-EPT (Isomer Design)
4-HO-EPT (Bluelight)
Experience Reports (1)
Tips (4)
Psychedelic tolerance builds rapidly. Wait at least 1-2 weeks between uses of 4-HO-EPT for full tolerance reset. Taking the same dose the next day would require roughly double the amount for comparable effects.
People with a personal or family history of psychotic disorders (schizophrenia, bipolar type I) should avoid 4-HO-EPT and other psychedelics. These substances can trigger or exacerbate psychotic episodes in predisposed individuals.
Set and setting are paramount with 4-HO-EPT. Choose a familiar, comfortable environment where you feel safe. Have trusted company or a trip sitter, especially for your first experience. Avoid stressful locations or social obligations.
Use a milligram scale to weigh 4-HO-EPT if it comes as a powder. Eyeballing doses of potent psychedelics is irresponsible. A quality 0.001g scale costs under $30 and could prevent a seriously overwhelming experience.
See Also
References (4)
- Psilocybin produces substantial and sustained decreases in depression and anxiety — Griffiths et al. Journal of Psychopharmacology (2016)paper
- Neural correlates of the LSD experience revealed by multimodal neuroimaging — Carhart-Harris et al. PNAS (2016)paper
- 4-HO-EPT - TripSit Factsheet
TripSit factsheet for 4-HO-EPT
tripsit - 4-HO-EPT - Wikipedia
Wikipedia article on 4-HO-EPT
wikipedia